GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston Pharmaceuticals, pledging another $800 million in milestone payments if the ...

GSK has moved to shore up its R&D pipeline with a strategic-level partnering deal with China's Jiangsu Hengrui Pharma.

Oscar Health shares fell despite no direct news as the company reported Q2 losses, reaffirmed sales guidance, and launched a new plan with Hy-Vee.